ECSP13013075A - Método de tratamiento de la fiebre dengue - Google Patents
Método de tratamiento de la fiebre dengueInfo
- Publication number
- ECSP13013075A ECSP13013075A ECSP13013075A ECSP13013075A EC SP13013075 A ECSP13013075 A EC SP13013075A EC SP13013075 A ECSP13013075 A EC SP13013075A EC SP13013075 A ECSP13013075 A EC SP13013075A
- Authority
- EC
- Ecuador
- Prior art keywords
- treatment
- dengue fever
- prophylaxis
- formula
- dengue virus
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000001490 Dengue Diseases 0.000 title 1
- 206010012310 Dengue fever Diseases 0.000 title 1
- 208000025729 dengue disease Diseases 0.000 title 1
- 241000725619 Dengue virus Species 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Esta solicitud proporciona métodos de tratamiento o profilaxis de enfermedades mediadas por el virus del dengue con compuestos de la fórmula I:en la que: R1, R2a, R2b, R3, R4, R5, R6, R8a, R9 y R10 tienen los significados aquí definidos. La solicitud describe además métodos de tratamiento o profilaxis de enfermedades mediadas por el virus del dengue con composiciones farmacéuticas que contienen compuestos de la fórmula I.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161495472P | 2011-06-10 | 2011-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP13013075A true ECSP13013075A (es) | 2014-01-31 |
Family
ID=46229500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP13013075 ECSP13013075A (es) | 2011-06-10 | 2013-12-10 | Método de tratamiento de la fiebre dengue |
Country Status (15)
Country | Link |
---|---|
US (2) | US20130018011A1 (es) |
EP (1) | EP2717881A1 (es) |
JP (1) | JP6072016B2 (es) |
KR (1) | KR20140041706A (es) |
CN (1) | CN103608020B (es) |
CA (1) | CA2837242A1 (es) |
CL (1) | CL2013003487A1 (es) |
CO (1) | CO6811865A2 (es) |
CR (1) | CR20130610A (es) |
EC (1) | ECSP13013075A (es) |
MX (1) | MX2013014389A (es) |
MY (1) | MY173636A (es) |
PE (1) | PE20141263A1 (es) |
RU (1) | RU2605904C2 (es) |
WO (1) | WO2012168348A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130018011A1 (en) * | 2011-06-10 | 2013-01-17 | Hassan Javanbakht | Method of treating dengue fever |
US20170022242A1 (en) * | 2014-04-17 | 2017-01-26 | Katholieke Universiteit Leuven, KU LEUVEN R&D | Novel antiviral and antitumoral compounds |
SG11201702430WA (en) | 2014-09-26 | 2017-04-27 | Riboscience Llc | 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication |
CN106132972B (zh) * | 2015-02-06 | 2018-08-31 | 银杏树药业(苏州)有限公司 | 用于治疗hcv感染的氨基磷酸酯 |
WO2017142984A1 (en) * | 2016-02-16 | 2017-08-24 | Riboscience Llc | Inhibitors of zika virus |
US20180098828A1 (en) | 2016-10-07 | 2018-04-12 | 3M Innovative Properties Company | Ceramic dental restorations made by additive manufacturing |
TWI794742B (zh) * | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2604620T1 (sl) * | 2003-05-30 | 2016-10-28 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Modificirani fluorirani nukleozidni analogi |
WO2007020193A2 (en) * | 2005-08-15 | 2007-02-22 | F. Hoffmann-La Roche Ag | Antiviral phosphoramidates of 4 ' -substituted pronucleotides |
US7964580B2 (en) * | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
EP2166016A1 (en) * | 2008-09-18 | 2010-03-24 | Centocor Ortho Biotech Products L.P. | Phosphoramidate Derivatives of Nucleosides |
MX2011006891A (es) * | 2008-12-23 | 2011-10-06 | Pharmasset Inc | Fosforamidatos de nucleosidos. |
US8552021B2 (en) * | 2009-09-29 | 2013-10-08 | Janssen Products, L.P. | Phosphoramidate derivatives of nucleosides |
EP2619215B1 (en) * | 2010-09-22 | 2018-09-05 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
US20130018011A1 (en) * | 2011-06-10 | 2013-01-17 | Hassan Javanbakht | Method of treating dengue fever |
-
2012
- 2012-06-05 US US13/488,802 patent/US20130018011A1/en not_active Abandoned
- 2012-06-07 PE PE2013002781A patent/PE20141263A1/es active IP Right Grant
- 2012-06-07 EP EP12726438.0A patent/EP2717881A1/en not_active Withdrawn
- 2012-06-07 CN CN201280029465.9A patent/CN103608020B/zh not_active Expired - Fee Related
- 2012-06-07 JP JP2014514062A patent/JP6072016B2/ja not_active Expired - Fee Related
- 2012-06-07 MY MYPI2013702389A patent/MY173636A/en unknown
- 2012-06-07 KR KR1020147000613A patent/KR20140041706A/ko not_active Application Discontinuation
- 2012-06-07 RU RU2013156939/04A patent/RU2605904C2/ru not_active IP Right Cessation
- 2012-06-07 WO PCT/EP2012/060781 patent/WO2012168348A1/en active Application Filing
- 2012-06-07 MX MX2013014389A patent/MX2013014389A/es unknown
- 2012-06-07 CA CA2837242A patent/CA2837242A1/en not_active Abandoned
-
2013
- 2013-11-21 CR CR20130610A patent/CR20130610A/es unknown
- 2013-11-29 CO CO13281371A patent/CO6811865A2/es unknown
- 2013-12-05 CL CL2013003487A patent/CL2013003487A1/es unknown
- 2013-12-10 EC ECSP13013075 patent/ECSP13013075A/es unknown
-
2015
- 2015-10-09 US US14/879,463 patent/US20160168186A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN103608020B (zh) | 2016-11-23 |
CL2013003487A1 (es) | 2014-09-05 |
US20160168186A1 (en) | 2016-06-16 |
MY173636A (en) | 2020-02-12 |
RU2013156939A (ru) | 2015-07-20 |
WO2012168348A1 (en) | 2012-12-13 |
CO6811865A2 (es) | 2013-12-16 |
JP2014519507A (ja) | 2014-08-14 |
CR20130610A (es) | 2014-02-18 |
KR20140041706A (ko) | 2014-04-04 |
EP2717881A1 (en) | 2014-04-16 |
CN103608020A (zh) | 2014-02-26 |
PE20141263A1 (es) | 2014-09-29 |
MX2013014389A (es) | 2014-03-21 |
CA2837242A1 (en) | 2012-12-13 |
JP6072016B2 (ja) | 2017-02-01 |
US20130018011A1 (en) | 2013-01-17 |
RU2605904C2 (ru) | 2016-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122266T1 (el) | Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων | |
CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
NI201600018A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
CO7170160A2 (es) | Nuevas 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infección del virus de la hepatitis b | |
ECSP13013075A (es) | Método de tratamiento de la fiebre dengue | |
UY32793A (es) | Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos | |
CR20160237A (es) | Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
IN2015DN01156A (es) | ||
CR20140312A (es) | 4-fenil-piridinas sustiuidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
CR20160337A (es) | Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b | |
UA113956C2 (xx) | Похідні піримідину для лікування вірусних інфекцій | |
CY1120438T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει μυο-ινοσιτολη και d-κιρο-ινοσιτολη | |
ECSP12012104A (es) | Inhibidores de virus flaviviridae | |
PE20151023A1 (es) | Triazolopirazinas | |
ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
TR201901886T4 (tr) | DNA-PK inhibitörleri. | |
GT201400111A (es) | Triazolopiridinas sustituidas | |
UY32848A (es) | Compuestos heterocíclicos de oxima | |
UY33924A (es) | Compuestos de triazolopiridina como inhibidores de cinasa pim | |
EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
EA201492016A1 (ru) | C-17 бициклические амины тритерпеноидов с ингибиторной активностью созревания вич | |
CL2016000150A1 (es) | Compuestos y composiciones como inhibidores de la mek | |
CY1118399T1 (el) | Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c | |
MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives |